NeuroMetrix (NASDAQ:NURO) Now Covered by StockNews.com

StockNews.com began coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research report report published on Thursday morning. The firm issued a sell rating on the medical device company’s stock.

NeuroMetrix Stock Up 4.5 %

NURO stock opened at $4.21 on Thursday. The company has a market capitalization of $8.59 million, a PE ratio of -0.92 and a beta of 2.20. The stock’s 50 day moving average is $4.03 and its two-hundred day moving average is $3.88. NeuroMetrix has a 52-week low of $2.66 and a 52-week high of $4.73.

NeuroMetrix (NASDAQ:NURO) last posted its quarterly earnings data on Tuesday, November 5th. The medical device company reported ($0.75) EPS for the quarter. NeuroMetrix had a negative net margin of 203.71% and a negative return on equity of 42.56%. The company had revenue of $0.59 million for the quarter. During the same quarter last year, the business earned ($1.66) EPS.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.